Cure My Disease

Don't miss your cure!

 Log in / Sign up

New immunotherapy targets tough pancreatic cancers in early trial

NCT ID NCT05726864

Disease control Sponsor: Elicio Therapeutics Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 10, 2026 · Updated 1 time

Summary

This early-phase trial tests an experimental immunotherapy called ELI-002 7P in people with pancreatic or other solid tumors that have specific KRAS or NRAS gene mutations. The treatment aims to train the immune system to attack cancer cells. About 158 participants will receive the drug or standard monitoring. The study checks safety and whether the treatment helps keep cancer from coming back.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

158 people

The number who actually took part.

Started

Apr 2023

Expected to finish

Nov 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * KRAS/NRAS mutated (G12D, G12R, G12V, G12A, G12C, G12S, G13D) solid tumor * Phase 1 only: positive for circulating tumor DNA and/or elevated serum tumor biomarkers (such as CA19-9 and CEA) despite prior standard therapy including surgery and chemotherapy/radiation therapy where applicable * Screening CT is negative for recurrent disease * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 Exclusion Criteria: * Presence of tumor mutations where specific therapy is approved * Known brain metastases * Use of immunosuppressive drugs

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Colorectal cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colonic neoplasm colorectal cancer colorectal neoplasm neoplasm pancreatic ductal adenocarcinoma rectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Colorectal cancer KRAS G12A KRAS G12C KRAS G12D KRAS G12R KRAS G12S KRAS G12V KRAS G13D NRAS G12C NRAS G12D NRAS G12R NRAS G12S NRAS G12V Pancreatic ductal adenocarcinoma

Contacts and locations

Locations

  • Banner MD Anderson Cancer Center

    Gilbert, Arizona, 85234, United States

  • Cedars-Sinai Medical Center

    Los Angeles, California, 90048, United States

  • City of Hope

    Duarte, California, 91010, United States

  • Dana Farber Cancer Institute

    Boston, Massachusetts, 02215, United States

  • Emory Winship Cancer Institute

    Atlanta, Georgia, 30322, United States

  • Lehigh Valley Health Network

    Allentown, Pennsylvania, 18003, United States

  • Massachusetts General Hospital

    Boston, Massachusetts, 02210, United States

  • Mayo Clinic Comprehensive Cancer Center

    Phoenix, Arizona, 85054, United States

  • Mayo Clinic Comprehensive Cancer Center

    Jacksonville, Florida, 32224, United States

  • Mayo Clinic Comprehensive Cancer Center

    Rochester, Minnesota, 55905, United States

  • Medical College of Wisconsin

    Milwaukee, Wisconsin, 53226, United States

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10022, United States

  • Moffitt Cancer Center

    Tampa, Florida, 33612, United States

  • New York Presbyterian Weill Cornell Medical Center

    New York, New York, 10065, United States

  • Northwell Health

    Lake Success, New York, 11042, United States

  • Ochsner Health

    New Orleans, Louisiana, 70121, United States

  • Sarah Cannon Research Institute

    Nashville, Tennessee, 37203, United States

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas, 77030, United States

  • University of California Los Angeles

    Los Angeles, California, 90095, United States

  • University of California, Irvine

    Orange, California, 92868, United States

  • University of Colorado Hospital-Anschutz Cancer Pavillion

    Aurora, Colorado, 80045, United States

  • University of Florida Health Cancer Center

    Gainesville, Florida, 32610, United States

  • University of Iowa

    Iowa City, Iowa, 52242, United States

  • University of Miami

    Coral Gables, Florida, 33124, United States

  • University of Michigan

    Ann Arbor, Michigan, 48109, United States

  • University of Pennsylvania

    Philadelphia, Pennsylvania, 19104, United States

  • University of Texas Southwestern

    Dallas, Texas, 75390, United States

  • Vanderbilt University Medical Center

    Nashville, Tennessee, 37212, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.